Abstract: A call notification system method, computer program and advertising method are disclosed. A call notification is generated at a recipient system (2) in response to receipt of initiation data on a call from an originating system (3). At least aspects of the call notification are controllable by the originating system (3).

Abstract: A call notification system method, computer program and advertising method are disclosed. A call notification is generated at a recipient system (2) in response to receipt of initiation data on a call from an originating system (3). At least aspects of the call notification are controllable by the originating system (3).

Abstract: A call notification system method, computer program and advertising method are disclosed. A call notification is generated at a recipient system (2) in response to receipt of initiation data on a call from an originating system (3). At least aspects of the call notification are controllable by the originating system (3).

Abstract: A call notification system method, computer program and advertising method are disclosed. A call notification is generated at a recipient system (2) in response to receipt of initiation data on a call from an originating system (3). At least aspects of the call notification are controllable by the originating system (3).

Abstract: A communication system is disclosed which is arranged to cause establishment of a connection between a first system that is a party to a call, or is a party to a call being initiated, and a second system. The first and second systems are arranged to communicate via said connection. The communication comprises a data dialogue that is separate to initiation communications for the call. At least one of the first system and the second system is arranged to store data, or to cause a change to an application or data or process in dependence on the data dialogue. A corresponding method is also disclosed.

Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.

Abstract: The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Abstract: A nucleic acid vaccine construct comprising an isolated polynucleotide which encodes a polypeptide comprising at least five consecutive amino acid residues from the VNTR monomer of Muc1 wherein one or more of said amino acids is a glycosylation site, characterised in that when said isolated polynucleotide is expressed in a mammalian cell, glycosylation of the resulting polypeptide is altered or prevented at at least one of said glycosylation sites.

Abstract: The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.

Abstract: A method is provided for securing data sets by dynamically hopping amongst a variety of data encryption and/or manipulation protocols. Such dynamic protocol hopping can be implemented in reconfigurable logic, or some combination of reconfigurable logic and fixed circuitry or software. The encryption and/or manipulation protocol applied to the data set is selected from among a plurality of encryption protocols in an, optionally upgradeable, library of protocols. Preferably, the selection can be driven by a random number generator. More preferably, the number of encryption protocols available can be extended using a logic-stretching engine. An apparatus is also provided for securing data, including a memory that contains data describing encryption protocols, a communications interface that is configured to receive data, and a processor that reads from the memory one of the encryption protocols and encrypts the received data based on the encryption protocol.

Abstract: The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases.

Abstract: A call notification system method, computer program and advertising method are disclosed. A call notification is generated at a recipient system (2) in response to receipt of initiation data on a call from an originating system (3). At least aspects of the call notification are controllable by the originating system (3).

Abstract: The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumors. In particular, the nucleic acid is DNA and the DNA constructs comprise a gene encoding a MUC-1 derivative having less than 10 perfect repeat units. The invention further provides pharmaceutical compositions comprising said constructs, particularly pharmaceutical compositions adapted for particle mediated delivery, methods for producing them, and their use in medicine. Novel proteins encoded by the nucleic acid and pharmaceutical compositions containing them are also provided.

Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Abstract: The present invention relates fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. In particular the fusion partners contain a so-called choline binding domain, for example fusions comprising LytA from Streptococcus pneumoniae, or the pneumococcal phage CP1 lysozyme (CPL1) wherein the choline binding domain is modified to include a heterologous T-helper epitope, and are fused to antigens, particularly poorly immunogenic antigens such as self-antigens, eg tumour specific or tissue specific antigens. The invention also relates to fusion proteins containing them, to their manufacture, to their use in immunogenic compositions and vaccines and to their use in medicines.

Abstract: The present invention relates to isolated immunogens and their use in the treatment of diseases that are treatable with neutralization of IL-13, such as COPD, asthma and atopic disorders such as hayfever, contact allergies and atopic dermatitis. In particular the invention relates to the neutralization of the biological effects of IL-13 by raising an immune response against the IL-13 by vaccination of a mammal with immunogens comprising the native or mutated amino acid sequence of IL-13, and foreign T-helper epitopes either inserted in, or attached to the IL-13 sequence or present in carrier polypeptides. Also provided by the present invention are DNA vaccines that comprise a polynucleotide sequence that encodes the immunogens of the present invention. The invention further relates to pharmaceutical compositions comprising such immunogens and their use in medicine and to methods for their production.

Abstract: The present invention relates to IL-13 vaccines and their use in the treatment of diseases that are treatable with neutralization of IL-13 such as COPD, asthema and atopic disorders such as hayfever, contact allergies and atopic dermatitis. The vaccines of the present invention comprise an IL-13 immunogen and an adjuvant composition which is a combination of saponin and an immunostimulatory oligonucleotide comprising at least one unmethylated dinucleotide. The invention further relates to pharmaceutical compositions comprising such immunogens and their use in medicine and to methods for their protection.

Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.

Abstract: Untranslated regions associated with the heat shock response can be used to obtain increased efficiency of translation of polypeptides that are not necessarily normally associated with the heat shock response. This allows the development of greatly improved expression systems. The invention is also useful, for example, in the treatment of a patient suffering from a deficiency in the expression of a polypeptide and in the provision of vaccines.

Abstract: The present invention relates to an isolated polypeptide useful for immunisation against self-antigens. In particular the invention relates to a self-protein that is capable of raising auto-antibodies when administered in vivo. The invention particularly relates to rendering human cytokines immunogenic in humans. The invention further relates to pharmaceutical compositions comprising such compounds and their use in medicine and to methods for their production.